Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite ...

Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

The discussion will cover the current CLL treatment landscape, including first-line and later-line options; the medical experts will review first-line treatments, approach to treatment selection, ...

The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and ...

A cancer diagnosis hits like a thunderbolt, changing lives instantly and profoundly. Victor Gonzalez, senior director of patient programs and support services at The Lymphoma Research Foundation, ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Relapsed/refractory CLL, I do kind of ...

Please provide your email address to receive an email when new articles are posted on . 61% of patients with heavily pretreated CLL responded to single-agent epcoritamab therapy. Researchers intend to ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center ...

Overwhelmed. That’s how some people describe chronic lymphocytic leukemia (CLL) diagnosis. Especially when you’re told to “watch and wait” rather than start treatment. Over 23,000 people in the U.S.